Physician profile
David Gay Morrison
NPI 1811904188
$22,795.13
in general payments reported to CMS, 2019-2025
90 companies · $3,518 in 2025
The $3,518 reported for 2025 was more than what 77% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $207 · 2020: $1,921 · 2021: $4,380 · 2022: $4,285 · 2023: $5,672 · 2024: $2,811 · 2025: $3,518.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $508.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,493.39 |
| Education | $508.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,507.99 | 2020-2025 | Enhertu, Tagrisso, Lynparza |
| Merck Sharp & Dohme LLC | $1,221.37 | 2020-2025 | Keytruda, Welireg, Lynparza |
| Novartis Pharmaceuticals Corporation | $1,142.95 | 2020-2025 | |
| E.R. Squibb & Sons, L.L.C. | $1,034.46 | 2019-2025 | Opdivo, Opdualag |
| Janssen Biotech, INC. | $986.92 | 2020-2025 | Rybrevant, Carvykti, Tecvayli |
| Bayer Healthcare Pharmaceuticals INC. | $855.89 | 2020-2025 | |
| Pfizer INC. | $846.49 | 2020-2025 | |
| Celgene Corporation | $842.54 | 2021-2025 | Reblozyl, Pomalyst, Opdivo |
| Glaxosmithkline, LLC. | $811.64 | 2020-2025 | Jemperli, Zejula, Ojjaara |
| Incyte Corporation | $799.03 | 2020-2025 | Jakafi, Monjuvi, Pemazyre |
| Amgen INC. | $768.17 | 2019-2023 | Kyprolis, Lumakras, Xgeva |
| Eisai INC. | $733.36 | 2020-2025 | |
| Astellas Pharma US INC | $706.13 | 2020-2025 | Xtandi, Vyloy, Xospata |
| Pharmacyclics LLC, An Abbvie Company | $693.33 | 2020-2023 | Imbruvica, Epkinly |
| Takeda Pharmaceuticals U.S.A., INC. | $675.94 | 2019-2025 | Ninlaro, Alunbrig, Iclusig |
Show all 87 companies
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Morrison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.